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Abstract
Eackground: Helminth infections are proposed to have immunomgdulatory activities affecting health outcomer either
detrimentally or benelicially. We evaluated the effects of albendazole treatment every three months for 21 month' on sTH,
malarial parasitemia and allergy.
Methods and Findings: A household-based cluster-randomized, double-blind, placebo-controlled trial was conduded in an
area in lndonesia endemic for STH. Using computer-aided block randomization, 481 households {2022 subjects) and 473
households (1982 subjects) were a5signed to receive placebo and albendazole, respectively, every three months. The
treatment code was concealed from trial investigators and panicipants. Malarial parasitemia and malaria-like symptoms
were assessed in participants older than four years of age while skin prick test (sPI) to allergens as well a! reponed
symptoms ofallergy in children aged 5-i5 years. The general impact oftreatment on sTH prevalence and body mass index
(BMl) was evaluated. Primary outcomes were prevalence of malarial parasitemia and sPT to any allergen. Analysis was by
intention to treat. At 9 and 21 months post-treatment 80.8% and 80.1% of the study subjects were retained, respectively.
The intensive treatment regiment resulted in a reduction in the prevalence of STH by 48% ln albendazole and 9% in placebo
group, Albendazole treatment led to a tranrient increase in maladal parasitemia at 6 months post treatment (oR 4.16(1.35
12.80)) and no natistically significant increase in SPT reactivity (OR 1.18(0,74-1,86) at 9 months or 1.37 (0.93-2.01) 21
months). No effect of anthelminthic treatment wa5 found on BMl, reponed malarialike- and allergy symptoms. No adverse
effects were reoorted.
Conclusions:The stody indicates that intensive community tr€atment of 3 monthly albendazole administration for 21 months
over two yea6leads to a reduction in STH. This degree of reduction appeaE safe without any increased risk of malaria orallergies-
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lntroduction
Soil transmitted helminths (STH) ftookworms, Ascaris lumbi'
coides and Trhhuris trichiura) establish chronic infections in a large
proportion of the world population.[l] Major intervention
programs using mass drug administration (tr4DA) to control
STH have been launched.[2] However, STH infections seem to
penist in the targeted populations raising concem over the
development of drug resistance.[3] It is therefore irnportant to
conduct well-designed studies that allow evidence-based decisions
to be made to maximize effective STH control toward elimination.
lVhile there is no doubt that STH are associated with
morbidities in billions of people worldwide, there is also increasing
awareness that helminth infections might, like bacterial commen-
sals, play an important role in shaping human health.[4]
Helminths may contribute to immunologic and physiologic
homeostasis. The immune system is thought to have evolved to
operate optimally in the face of helminth-induced imrnune
regulation, and that any disturbance of this long evolutionary
co-existence between humans and helminth parasites might be
associated with the emergence of pathological conditions[S]
# Agc >2 ycars old (scrniqbm)
& 5-l5 ycan old (runl)
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possibly involving outcomes of exposure to other pathogens or
the development of inflammatory diseases.
In many parts of the world helminths and malarial parasites are
co-endemic raising the question of what impact helminth
infections may have on the plasmodial parasites that cause
malaria. The results have been conflicting in this regard. In some
studies a positive association has been reported between helminths
and malarial parasitemia while in othen, this has been refuted or
in yet others a negative association has been shown between
helminths and the severity of the clinical outcomes of malaria
(reviewed by Nacher).[6]
An increase in the prevalence of allergies has been reported
worldwide, in particular in the urban areas of low- to middle-
income countries.[7] Although majority of cross-sectional studies
have reported invene associations between helminth infections
and allergies[8,9], two randomized trials with albendazole, have
shown conflicting results. One in Ecuador, based on school
randomization, reported no change in either SPT reactivity to
allergens or allergic symptoms after one year of albendazole
treatment[O] while another in Vietnam, in which the random-
ization unit was individual schoolchildren, showed increased SttT
reactivity after one year of albendazole treatrnent, but consistent
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Figure 1. Trial Profile. HH: Household. Lost to follow up implies that the participants have
absent implies that the participants have no data at this time point but have data available at
doi:1 0.1 371 /journal.pone.0057899.g001
no data from this time point onward. Temporarily
other time point.
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with the Ercuadorean study, clinical allergy did not change
significantly. I l] It has been suggested that anthelminthic
treatrnent of longer duration might be needed to reveal the
modulatory elfect of helminths. [ 2, I 3]
In the light of global deworming initiatives, it is important to
assess the effectiveness of and to monitor the risks associated with
anthelminthic treatment regiments. There is as yet no report of a
household-based cluster-randomized double-blind placebo-con-
trolled trial of repeated anthelminthic administration in a
community that would be expected to more elfectively reduce
transmission of STH by decreasing household cross-contamina-
tion.
In an area where STH and malaria are co-endemic on Flores
Island, Indonesia, we conducted a household cluster-randomized
trial of three-monthly a^lbendazole treatrnent over a two year study
period in a whole community to assess benefits and risks associated
with this anthelmintic treatrnent. Specifically we assessed its
impact on STH, malarial parasitemia and allergy.
Methods
Study population and design
This trial was conducted in two villages in the Ende District of
Flores Island, Indonesia (Appendix Sl, p2) as described in detail
elsewhere.!4,15] The treatrnent was based on household and
given to all household members except those less than two ye.rs
old or pregnant (the Indonesian national program guideline).
Direcdy observed treatment was given three monthly during the
trial period (fune 2008 toJuly 2010, with treatrnent starting in
Sept 2008). The primary outcomes were prevalence of malarial
parasitemia and SPT reactivity to allergens. Additional outcomes
were treatrnent effect on STH and BMI as well as malaria-like and
allergy symptoms.
We measured malaria outcomes in Nangapanda only. Malaria
was not endemic in Anaranda. Artemisinin-combination therapy(ACT) treatrnent and reated bed net distribution were not
implemented during our study period.[6,17]
Allergy outcomes were measured, in both villages, in school-age
children (5-15 yean old) as this group is particularly at risk of
developing allergy and asthma[B] and is the target population of
global deworming programs.
The study was approved by the Ethical Committee of the
Medical Faculty, University of Indonesia (ethical clearance ref
194/PI02.FK/Etik/2006) and filed by the Committee of Medical
Ethics of the Iriden University Medical Center. The trial was
registered as clinical trial (Ret ISRCT'NB3B30BI4). Prior to the
study, written informed consent was obtained from participants or
from parents/guardians of children. The study is reported in
accordance with the CONSORT guidelines for cluster-random-
ized studies. The protocol for this trial and supporting CON-
SORT checklist are available as supporting information; see
Checklist Sl and Protocol Sl.
Randomization and masking
The population was randomized by IA using computer aided
block randomization at household level utilising Random Alloca-
tion sofnvare to receive albendazole (single dose of 400 mg) or a
matching placebo (both tablets from PT Indolarma Pharmaceu-
tical, Bandung, Indonesia). The treatrnent code was concealed
from trial investigators and participants. The un-blinding of
treatrnent codes occurred after all laboratory results had been
entered into the database (August 20ll).
PLOS ONE I www.plosone.org
Procedures
Trained community worken measured fever, administered
monthly malaria-like symptoms questionnaire which was based
on WHO definitions[9] and took finger-prick blood for the three-
monthly malarial parasitemia survey. Subjects with fever
(>37.5'C) or additional malaria-like slrnptoms fteadache, fatigue
and nausea) at the time of visis were referred to the local primary
health centre (puskesmas). Thick and thin Giemsa-stained blood
smears were read at Univenity of Indonesia. At baseline, 9 months
and 2l months after the first round of treatment blood was
collected for PCR-based detection of Pksnodium spp. (Appendix Sl,
p2), a method that is more sensitive than microscopy.[20]
Regarding allergy outcomes, skin prick tests (SPT) wit}r
allergens were performed on school-age children in Nangapanda
and Anaranda and clinical s)'rnptoms of allergy were recorded.
House dust mite (Dnnatopltagoida ptnonyssinus and D. farinat, klndly
provided by Paul van Rijn from FIAL Allergy l,aboratories,
Iriden, The Netherlands) and cockroach (Blntzlln gernanica;
Iofarma, Milan, Italy) were used for SPT which was considered
positive with 3 mm cut o{f.[4] The SPT was performed by one
investigator. IgE with specificity for aeroallergens (D. pttronlssinus
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1. Baseline characteristics.
2022 1O9O t53.9) 1982 1042(52.61
683 7 (r.0) 629 18 (2.9)
1225 26 {2.1)
Mafarial parasitemia (any spp]'t 772 195 (25.3) 739
772 102 (13.2) 739 93 (r2.6)
88 (r2.4) 6s3 7s (r r.s)
rdiagnosed by PcR; 2diagnosed by microscopy.
The number of positives (n) of the total population examined (N).
doi:'l 0.'l 37 1 /journal.pone.0057899.t00 I
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Figure 2. A) Percentage of helminth infected subjcGts in placebo and albendazole treatment arms. The presence of hookworms (by
PCRI, Ascoris lumbricoides (by PCR) and Trichuris trichiura (by microscopy) or any of these helminth infections in subjects who provided stool samples
at baseline, 9 and 21 months post treatment (numbers are given in table Sl A in Appendix 51). B) Effect of albendazole treatment on reduction
in the intensity as well as percentage of subjects positive for hookworm and Ascarisinlection as determined by PCR. Negative is when
no helminth specific DNA was found. Positive Ct- values were grouped into three categories: Ct<30.0, 30.0<Ct<35.0 and >35.0 representing a high,
moderate and low DNA load, respectively.
doi:l 0.1 37 I /journal.pone.0057899.9002
and B. germanba) was measured in plasma using an ImmunoCAP
250 system (?hadia, Uppsala, Sweden) following the manufactur-
er's instructions. AIl measurements were conducted in one
laboratory in the Netherlands. Syrnptoms of asthma and atopic
dermatitis were recorded using a modified visually-assisted version
of the International Study of Asthma and Allergy in Childhood
ISAAC) questionnaire as reported before.[4]
Yearly stool samples were collected on a voluntary basis.
Tichuis was detected by microscopy and a multiplex real-time
PCR was used for detection of hookworms (Ancylostoma duodmale,
Necator amaicanus), .Ascarb ltmbritoifus, and Strongloifus sttrcoralis
DNA as detailed beforeflS] (Appendix Sl, p2). Very few subjects
were infected with S. sttrcoraliu and therefore this infection was not
included in analyses.
Body weight and height were measured using the National
Heart Lung and Blood Institute practical guidelines (scale and
microtoise from SECA GmBH & Co, Hamburg, Germany).
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Power calculation
Sample size estimation was based on the expected change in
primary outcomes taking into account a power of 90% and a
signilicance level of <0.05 with a loss to follow-up of 20%. Based
on previous observations we expected to find a decrease in
malarial parasitemia prevalence and an increase in SPT reactivity
after anthelminthic treatment. Based on a prevalence of about
l0% and a risk ratio (RR) of 0.60 we aimed to include 2412 people
in the malaria assessments. In a pilot study we found SPT to D.
pterorytssinus to be around l5%, and expected that due to treatrnent
the preva.lence would increase. In order to find a RR of 1.5 we
aimed to include at least l4l8 children.
Statistical analyses
For children 319 years, BMI age-standardized z-scores were
calculated according to IVHO references. [2 l] The IgE data were
log-transformed to obtain normally distributed variable. To assess
treatment effects generalized linear mlxed models were used which
provide a flexible and powerfirl tool to derive valid inference while
Albendazole
N. tmorlctnus
PLOS ONE I www.plosone.org March2013 lVolume 8 | lssue 31e57899
A. lumbrlcoldcs
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Flgure 3. Cftect ot.lbcnd.tolc traat'nant on malarial parasitemla bas€d on two eg€ categorles. Malarial parasitemia A) <15 and B) >l5
years ofage. The risk of malarial parasitemia after albendazole treatment.ompared to placebo is shown as odds ratio with 95% Cl. The referen<e line
is set at 1, indicating that symbols at the right ofthis line represent an increa5ed risk while syrnbols at the l€ft ofthe line would predict decfeased risk
of malarial parasitemia- Note: at 9 month time point in those >15 years of age, the OR i5 a.
doi:l 0.1 371 /journal.pone.00578999003
captudng the data corrclations induccd by clustering within
households and rcpeated elaluations in time of thc samc subject.
Paraneter estimatcs for tr€atrnent efects at 9 and 2l months and
950,6 confidence intervals are reported. The reportcd Fvalues are
obtained using likelihood ratio test by comparing thc model with
and without the teagnent efect. Unl6s stated otherwise all
outcomcs wele adjusted for a{€a (the two study villages in Ende
District: Nangapanda or Anaranda) as colariate in thc model. l'or
the continuous outcomes 0inear mixed-effects modcls[22] were
used with three random effects, namely to model clustering within
households a random household specific intercept was used and to
model correlation within subjects a random subject specifrc
intercept and slope were used. For the binary outcomes a logistic
model was used with random household cfece and random
subject cftects. All models were fitted using the lrne4 package
(Appendix Sl, p6-7).[23] For cach fever and additional malaria-
like symptoms, total numbcr of events and person months are
computed for each treatrnmt arm. Hazard ratios for elfect of
Ecarnent werc ca.lculated with Cox rcgression with robust Sll to
allow for within-hous€hold clustcring (STATA I l).
Results
At baseline, 954 houscholds with 4004 subjccs were registered.
Randomization ofhouseholds resulted in l9B2 people assigned to
a.lbendazole tr€atment and 2022 p€ople to placebo (473 and 4Bl
houses respectively). At baseline 87'3"/" of the individua.ls were
infected with one or more h€lninth species. The baseline
Table 2. Effect of three'monthly albendazole treatment on malaria outcomes: Percentage of subjects with malarial parasitemia.
Odd3 Rrtlo (95%Cll Odd3 R.tlo (95%Cll
M.l..l.l p.r..trrnl. bt 6l.ror.opy
0 month 32/122512.6)
3 months 411lil',7 146)
6 monrht 8/815 (1.0)
9 monlhs l4l917 0.5)
12 months 9/834 (r r)
15 monthr fin73/J8l
18 months 3/815 (0.4)
2r months 61821(0.,
lit.l.rl.l p.r.ilte|nl. by PCR
0 momh 16n72 {3.n
9 months 151656 (5.3)
2l monthr 21l5a4 05)
2a/1187 12.4)
46/9t0l5.t)
2An94 Q.5)
7t oQ.n
9/8r3 (r.1)
13n72 (.7)
10/801 (1.2)
I l/824 {1.3)
2tt9 {152)
56/627 18.9)
31/553 {5.6)
26/122512.11
17/497 0.9)
4/815 (0.5)
4t947 tO_4)
4/834 {0.5)
3nn QAI
r/8r5 (0.1)
&424lo.7l
102n72|J321
56/656 (8 5)
2,V584 (4r)
r 8/r 187 (1.5)
24910 Qrl
9/194 11.11
s/95010J)
2/8t3 (0.2)
4n12lO_5)
r/803 {0.1)
o
93n39 (2.61
501627 |3A)
27/ss3 (4.91
7/1225lO.2)
r/897 (0.r)
0
1/917 {0.1}
0
1mtlo.1)
r/815 {0.r)
3/824 (0.4)
ton72 /,|3)
7165611.11
t0/584 (1.7)
7/1141 \0.6)
6,9t0 (0.7)
0
l/950 {0.1)
0
3n72lol)
1/803 (0 I )
1/824 {O1)
147t9 tlll
9/677 11 .4)
5As3 (09
The number of posiriver (n) of the rotal popularion examined (N).
ll714oum.l.pone.m57899.t0O2
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spp)
3. Effect of three-monthly albendazole treatment on
malaria outcomes: Malarial parasitemia by microscopy
Placebo Albendazole OR (95%C1 '
6 months 12/8r5 (1.5) 29n94 13.7' 4.16 (1.3s-r2.80)
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were equally d.istributed between the treatment arms. At 9 months
post-treatrnent full compliance was 77.8o/o for albendazole
treatrnent and 78.0% for placebo. This was 63.1% and 62.50/o
respectively at 2l months.
This intensive treatment with albendazole resulted in a
reduction but not elimination of STH. There was a decrease
both after 9 (OR (95% CI) = 6.6, (0.04=0.1 l) and 2l months (0.05
(0.03 O.08) of treatment (p<0.0001). Albendazole had the largest
effect on hookworm followed byr4sraru while the effect on Trithuris
was less pronounced (figure 2A and table Sl in Appendix Sl pB).
Treatrnent also led to statistically signficant reduction in the
intensity of hookworm and,4srarir infection as determined by PCR
(figure 2B). The fact that the stool sampling was on a voluntary
basis could have created a selection bias. Analyzing baseline
characteristics of subjects providing stool samples and those who
did not at 9 months follow up, showed no di{ferences in helminth
prevalence, age and sex. Although at 2l months post treatment,
sex and helminth prevalence were not diferent, age was slightly
but significandy higher in subjects who provided stool samples
mean age in yean (SD) = 29.9 (20.4) vs 24.3 (17 .5), p = 0.006)
The overall percentage of subjects with malarial parasitemia,
irrespective of treatrnent arm, decreased over the trial period
(table 2). However, when the data were modelled to assess the
effect of albendazole treatrnent over time, there was a significant
(P=0.0064) increase, which might result from the transient four-
fold increased risk of malarial parasitemia (OR 4.16 (1.35 12.80)
(table 3) at 6 months after initiation of treatment (after 2 doses of
albendazole). The effect of anthelminthic treatrnent was assessed
in those younger than 15 years of age who would be the prime
target of the global deworming programs. The transient increase
in parasitemia was only seen in the older (>15 years) age group
(figure 3). Malarial parasites were also assessed by PCR, at 9 and
2l months after initiation of treatrnent and revealed that
albendazole had no elfect when all Plasnodirm species were
considered together, but when analyzed separately there was a
significant increase in the percentage of subjects positive for P.
falriparun at 9 months post-treatrnent (table a). There was no
difference in the incidence of Gver and additional malaria-like
sFnptoms between the two treatrnent arms (table 52 in Appendix
Sl pl0).
The proportion of subjects with SF.I reactivity was 353/1364
(25.9Vo) at baseline. Albendazole treatrnent had no statistically
significant effect on SPT to any allergen (table 5), but it was noted
that there was an incremental increase in the risk of being SPT
positive to any allergen at 9 months and 2l months post initiation
oftreatrnent. Moreover, additional analysis on allergens separate-
ly, showed a significandy higher SPT to cockroach at 2l months
after treatrnent (1.63 (1.07-2.50)) (table 6). The levels ofIgE to
allergens showed that albendazole treatrnent had no effect (table 6).
No effect of treatment was seen on symptoms of asthma or atopic
dermatitis (table 53 in Appendix Sl pll).
No significant change in BMI was observed in children or in
adults (table 54 in Appendix Sl pl2). Moreover, there was no
adverse e{fect of treatrnent reported.
Discussion
This household-based clustered-randomized, double-blind, pla-
cebo-controlled trial shows that administering a total of seven
single doses of albendazole, at three-monthly intervals, to a
population living in an area of lndonesia where STH are higtrly
prevalent, leads to decreased prevalence of helminth infections
which although statistically significant, can be taken as an
incomplete reduction. The results show a bansient increase in
9 months 191947 (2.01 13l9so (1.41 0.57 (0.16-2.04)
12 months l31834 (1.6) 10/813 (r.2) 0.62 (0.12-3.1s)
I I months s/81 s (0.6) 1.84 (0.12-29.03)
The number of positives (n) ofthe total population examined (N).'Odds ntio
and 95% confidence interyal are based on mixed effects logistic reglession
models. OR's and 95% Cl are shown for the separate time points on malarial
parasitemia. The p-value is generated from the modeled data for the combined
effect of albendazole treatment over time, which is significant (P = 0.0041) and
might result from the effect of 6 months post treatment time point.
doi:1 0.1 371ljournal.pone.0057899.t003
characteristics were similar between the treatment arms (table l).
The overall trial profile is shown in figure l, and figure SlA, SlB,
SIC (pl3 15) in Appendix Sl separately for malaria, allergy and
helminth outcomes. The analysis was intention-to-treat and
involved all participants as assigned randomly at the start of the
trial. During the study, in the albendazole arm 6l people moved to
a house that was assigned to placebo while in the placebo arm 62
people moved to a house that was assigned to albendazole. The 44
subjects who died during the trial, included 4 people below the age
of20, 3 between 20 and ttO and the rest above 40 years ofage, and
Table 4. Effect of three-monthly albendazole treatment on
malaria outcomes: Malarial parasitemia by PCR.
Albendazole
Malaria (any spp)
9 months 95/656 (14.5) 1031627 (16.41 1.13 (0.77-1.64)
21 months 53/584 (9.1) 591553 (10.7) 1.09 (0.68-1.76)
9 months 3sl6s6 (5.3) s6/627 (8.9) 2.82 (1.29-6.151
21 months 24/5U (4.1't 27/553 t4.9) 1.40 (0.s6-3.s2)
9 months 9/627 (1.4) 0.34 (0.04-2.79)
The number of positives (n) of the total population examined (N). Odds ratio
and 9596 confidence interual based on logistic mixed models. The statistically
significant results are given in bold. The p-values are generated from the
modeled data for the combined effect of albendazole treatment over time for
each of the species separately, which were significant for P. falciporum
(P 
=0.029) and P. maloilae (P=0.016).
doi:1 0. 1 37'l /journal.pone.0057899.t0O4
parasitemia (any
oR (9s% cr)
'. vivax
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months
months
n/N (o/o)
5. Effect of three-monthly albendazole treatment on
outcomes: Skin prick test to any allergens.
Albendazole OR (95%Ct) .
to any allergen
months 145/455 131.9) 161/439 (36.7'1 1.37 (0.93-2.01)
The number of positives (n) of the total population examined (N).'Odds ratio
and 95% confidence interyal are based on mixed effects logistic regression
models. OR's and 95% Cl are shown for the separate time points on SPT to any
allergen. The p-value is generated from the modeled data for the effect of
albendazole treatment overtime and no significant effects were found (P>0.05).
doi:1 0. 1 371 /journal.pone.0057899.t005
malarial parasitemia in the albendazole- compared with the
placebo-treated arm in the first six months after initiation of
treafnent. Albendazole treatrnent had no statistically siglificant
effect on the desigrrated co-primary outcome, skin prick test
reactivity to allergens.
The clinical data collected of fever and additional malaria-like
symptoms, were not affected by the deworming. Clinical signs of
asthma and atopic dermatitis were also not affected by albendazole
treatment.
The prevalence of infection was high (>60%), which reflects the
situation in many areas that are being targeted by the global
deworming programs. Using a three-monthly treatrnent regimen
which represents an extreme scenario for helminth control
strategy, percentage of subjects positive for STH was reduced by
39% compared to placebo. It should be noted that in our study the
sensitive PCR method has been used. The reduction in the
proportion of subjects infected with hookworm and Ascans was
more pronounced than for Trichuris infections, confirming the
findings using a single dose of albendazole.[24] Subjects who
provided stool samples at 2l months were slighdy but significantly
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older than those who did not. Given that hoolnvorm infection is
more prevalent in older subjects, this may have contributed to the
poor deworming achieved by albendazole. The reduction achieved
in worm loads, did not have any beneficial e{fect on BMI.
Observational studies have reported that helminth infections allect
growth; however randomized trials have not been consis-
tent.[25,26] In this regard, our study would support the outcome
ofa recent Cochrane review ofno beneficial effect ofdeworming
programs on nutritional indicators [27] even though it can be
argued that in our study the suboptimal reduction in the STH
would not allow any beneficial elfect of anthelmintic in terms of
BMI to be seen in the community. Importantly, the fact that the
effect of such an intensive deworming strategy in a community is
incomplete, needs to be considered in the agenda for the control
and elimination of helminth diseases of humans.[Z8]
Most studies on the effect of helminth infections on malarial
parasitemia and clinical malaria episodes have used cross-sectional
designs and have been inconclusive.[6] longitudinal studies of
anthelminthic treatment have also reported conflicting re-
sults.[29,30] A small study conducted in Madagascar[29] has
reported an increase in malarial parasitemia in levimasole treated
subjects, older than 5 years of age, while in Nigeria [30],
albendazole treatrnent ofpre school children was associated with
lower P. fabiparum infection and anemia, however, the lost to
follow up in this study wns very high. The question whether
albendazole treatrnent during pregnancy could affect health
outcomes in the offspring, was addressed in a recent report from
Uganda.[3l] It was found that the incidence of malaria up to one
years of age was not different in the olfspring of mothers born to
those treated with albendazole or placebo. Our study, reports the
resulb of a community wide randomized-controlled trial that used
three-monthly malarial parasitemia data obtained by microscopy.
A significandy higher percentage of subjects positive for malarial
parasites in the albendazole compared to the placebo arrn was
seen but this seemed to be a transient effect and restricted to
individuals older than 15 yean ofage, an age group that is not the
main target of the current deworming programs. The question
Table 6. Effect of three-monthly albendazole treatment on allergy outcomes: Skin prick test and specific lgE to aeroallergens.
Albendazole
House dust mite
2l months
9 months
77l4ss (16.9\
60/462 {13.O}
N (Median, IQR)
76/439 (17.3)
65/454 (14.3|
N (Median, IQR)
1.37 (0.62-3.02)
1.27 (0.75-2.151
p (es% c019E-
9 months 391 (0.46, 0.16-2.35) 381 (0.46,0.14-r.98) r.0r (0.9r-1.12)
21 months 339 (1.83, 0.47-5.44\ 334 (1.64, 0.424.82\ 0.98 (0.85-r.r4)
The number of positives (n) of the total population examined (N).'Odds ratio and 95% confidence interual based on logistic mixed models; "0 (beta) and 95%
confidence interval based on generalized linear mixed models from the log-transformed lgE. The values shown are back-transformed. The p-values are generated from
the modeled data for the effect of albendazole treatment ovenime and no siqnificant effects were found (P>0.05).
doi:l 0.1 371 /journal.pone.0057899.t006
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arises as to why this effect was only seen in those ) 15 years ofage.
'fhis could be due to the fact that lscans infection is lower in older
age and therefore more easily cleared. It has been suggested that
Auaris is the spesies of helrninth that has the most effect on
malarial parasitemia and diseases.[6] Therefore by removing
Ascaris rn older age, we might be seeing a more profound effect on
malarial parasitemia.
Using PCR, which enables detection of sub-microscopic
infections at species level, it was also concluded that albendazole
did not alfect overall malarial parasitemia. \!'hen malaria species
were analyzed separately, the percentage of subjects inlected with
P. fabiparum but not with P. uiaax inueased significantly in the first
9 months post-treatment in the albendazole-treated arm, which is
contrary to our hlpothesis that anthelminthic treatrnent would
reduce prevalence of malarial parasitemia.[32] It was expected
that by decreasing STH, the immune hlporesponsiveness would
be reversed and this would be associated with stronger immune
effector responses to malaria parasites. One of the possible
explanations for the enhanced malarial parasitemia would be that
with a reduction in STH, there is increased nutrient availability for
other co infections and their growth.
It has been suggested that there are different malaria outcomes
with different species of helminths; Ascaris beng associated with
protection regarding parasitemia and severity of malaria while
hookworm with higher incidence of malaria. [6] Our study was not
powered to conduct a stratified analysis, and with the overall
gradual decrease in malaria in the study area during our study, the
numbers of subjects positive for malaria parasites are too few for
an ad hoc analysis.
The findings concerning allergy outcomes, although not
signifrcant, are in line with our hlpothesis that anthelminthic
treatment would increase SPT reactivity. The risk of SPT
reactivity increased incrementally with longer treaEnent and raises
the question whether even longer deworming periods are needed
for more pronounced effects on allergic outcomes. In support of
this, a recent study reported that 15 17 yean of ivermectin
treatrnent for onchocerciasis control in Ecuador led to a significant
increase in SPT reactivity to allergens.[2] In the same country,
one year of anthelmintic treatment in schoolchildren did not lead
to any change in SPf.!0] The question whether different species
of helminths might a{fect allergic outcomes to a different degree,
remains unanswered. It is interesting that a one year anthelmintic
treatrnent in Vietnam where hoolnvorm infection was the
prominent species, as in our study, resulted in a significant
increase in SPT positivity in schoolchildren. This is in contrast to
what was seen in Ecuador where Ascaris lumbrieoides was the most
prevalent species. One corunon leature of the anthelmintic trials
seems to be that clinical s)'rnptoms of allergy do not change with
deworming. However, an important trial in pregnant women in
Uganda has shown an increased risk of inlantile eczema in infants
of mothers treated with anthelminthics compared to those that
received placebo.[33] This could indicate that exposure to worms
in ear\ life, might allect allergic outcomes more profoundly than
when helminths are removed later in life.[34]
One of the limitations of this trial is the overall decrease in
malarial parasitemia during the two year study period, most
probably caused by actively referring subjects with malarialike
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